Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 5:49 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2113–2136 of 3,500 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Protein Control Clear all

Conditions: Bacterial Sepsis
Interventions: CPG 7909, J5-OMP Vaccine, Placebo; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Octreotide, Sputum
Interventions: Octreotide; Drug
Lead sponsor: Danbury Hospital; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Danbury, Connecticut

Conditions: Primary Cervical Dystonia, DYT 1 Dystonia
Interventions: Primary Cervical Dystonia (Trihexyphenidyl), Controls Primary Cervical Dystonia (Trihexyphenidyl), DYT 1 Dystonia (Healthy Control), DYT 1 Dystonia; Drug · Other
Lead sponsor: University of Florida; Other
Eligibility: 7 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Lymphoma, B-Cell
Interventions: CC-220, Polatuzumab vedotin, Rituximab, Tafasitamab, Gemcitabine, Cisplatin, Dexamethasone, Bendamustine, Lenalidomide; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 3
States / cities: Boston, Massachusetts • Ann Arbor, Michigan • Sioux Falls, South Dakota

Conditions: Hematologic Disease, Hemophilia A
Interventions: Kogenate (BAY14-2222); Drug
Lead sponsor: Bayer; Industry
Eligibility: 30 Years to 45 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 3
States / cities: Aurora, Colorado • Chapel Hill, North Carolina • Houston, Texas

Conditions: Fatty Liver, Nonalcoholic, Liver Diseases
Interventions: Ketogenic Diet, Standard Weight Loss Diet; Other
Lead sponsor: Marc Goodman; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Interventions: TI Inhalation Powder and Humalog (Amendment 1), TI Inhalation Powder (original protocol); Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Santa Barbara, California

Conditions: Epilepsy, Focal Seizures, Partial Seizures
Interventions: Natalizumab, Placebo; Drug · Other
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 31
States / cities: Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 26 more

Conditions: Ovarian Cancer, Ovarian Neoplasms
Interventions: Vigil, Placebo; Biological · Other
Lead sponsor: Gradalis, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 26
States / cities: Mobile, Alabama • Irvine, California • San Francisco, California + 22 more

Conditions: Body Composition Changes, Body Weight Changes, Anthropometric Changes, Metabolism Changes, Hemodynamic Changes
Interventions: Thermogenic dietary supplement, Protein supplement, Placebo supplement; Dietary Supplement
Lead sponsor: Texas Tech University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Healthy
Interventions: a non-traditional (i.e., not typically available in the supermarket) blueberry cultivar bred using natural plant breeding techniques and established as having enhanced nutritive value, a standard commercially available blueberry variety (i.e., cultivar), a "minimally processed" blueberry-rich protein bar, a control beverage of matched-nutritive content; Other
Lead sponsor: North Carolina State University; Other
Eligibility: 25 Years to 65 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Kannapolis, North Carolina

Conditions: Vaccine Reaction
Interventions: FMP014, ALFQ; Drug
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 55 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Substance-Related Disorders
Interventions: D-cycloserine, Placebo; Drug
Lead sponsor: Boston University Charles River Campus; Other
Eligibility: 18 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Obesity
Interventions: Tirzepatide, Mibavademab, Tirzepatide-Placebo, Mibavademab-Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 392 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 17
States / cities: Gardena, California • Irvine, California • Los Angeles, California + 14 more

Conditions: Food Hypersensitivity
Interventions: Peanut SLIT, Placebo SLIT; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 1 Year to 11 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Diabetes Mellitus, Type 2
Interventions: albiglutide, Oral contraceptive (Brevicon); Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Hepatitis C, Liver Transplantation
Interventions: cyclosporin (Neoral), tacrolimus (Prograf); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 9
States / cities: Phoenix, Arizona • Palo Alto, California • San Francisco, California + 5 more

Conditions: Type 2 Diabetics, Chronic Kidney Disease, Protein in Urine
Interventions: ABT-614, Placebo Comparator; Drug
Lead sponsor: Abbott; Industry
Eligibility: 19 Years to 70 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Diffuse Hemispheric Glioma, H3 G34-Mutant
Interventions: Dendritic Cell Tumor Peptide Vaccine, Ipilimumab, Leukapheresis, Nivolumab, Placebo Administration, Poly ICLC, Resection; Biological · Procedure · Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 13 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Ovarian Cancer
Interventions: Exercise and medical nutrition; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: New Haven, Connecticut • Miami, Florida

Conditions: Arthritis, Psoriatic
Interventions: CZP 200 mg Q2W, CZP 400 mg Q4W, Placebo; Biological · Other
Lead sponsor: UCB BIOSCIENCES GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 409 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 27
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama • Peoria, Arizona + 24 more

Conditions: Hepatocellular Carcinoma (HCC)
Interventions: HLX13, Yervoy, OPDIVO; Drug
Lead sponsor: Shanghai Henlius Biotech; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 11
States / cities: Glendale, California • Jacksonville, Florida • Margate, Florida + 7 more

Conditions: Autism
Interventions: secretin, synthetic porcine, secretin, biologically derived porcine; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 3 Years to 12 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2000
U.S. locations: 2
States / cities: Denver, Colorado • Seattle, Washington

Conditions: Turner Syndrome
Interventions: Humatrope; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 4 Years to 20 Years · Female only
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2015
U.S. locations: 9
States / cities: Los Angeles, California • Aurora, Colorado • Hartford, Connecticut + 6 more

Search by objective public record fields.

Detoxified J5 Core Glycolipid/ Group B Meningococcal Outer Membrane Protein Vaccine for Gram-negative Bacterial Sepsis Administered With and Without Synthetic CPG Oligodeoxynucleotide 7909 Adjuvant

Octreotide for Management of Bronchorrhea in Mechanically Ventilated Patients

Neuroimaging of Dystonia

Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma

BAY14-2222 Prophylaxis and Joint Function Improvement (Adults)

Ketogenic Diet in Non-alcoholic Fatty Liver Disease

Safety and Efficacy of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder)When an Optimal Dose is Taken With Varied Carbohydrate Intake

Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy

A Trial of Vigil for Participants With Ovarian Cancer

Chronic Thermogenic Dietary Supplement Consumption

Evaluating the Availability of Berry Phytonutrients Post-consumption of Fresh and Processed Blueberry by Healthy Adults

A Trial For The Study of Falciparum Malaria Protein 014 Administered Via Intramuscular Injection in Healthy Adults

Efficacy of D-Cycloserine for Enhancing the Effects of CBT for Substance Use

A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity

A Study of Sublingual Immunotherapy in Peanut-allergic Children

An Evaluation of the Pharmacokinetics of an Oral Contraceptive (Brevicon) When Co-administered With Albiglutide .

Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C

A Study to Evaluate the Safety and Tolerability of ABT-614 and Its Effect on Kidney Function in Subjects With Type 2 Diabetes and Chronic Kidney Disease With Protein in Their Urine.

Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant

Trial of Exercise and Lifestyle for Women With Ovarian and Endometrial Cancer

Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis

Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma

Secretin for the Treatment of Autism

Long-Term Growth and Skeletal Effects of Early Growth Hormone Treatment in Turner Syndrome